| |JANUARY 20259PHARMA EXPORTS SURGE TO RS 2.3 LAKH CRORE IN FY24, DOUBLING SINCE FY14INDIA'S PHARMA INDUSTRY LEADS AS A TOP INVESTMENT MARKETIn the financial year 2024, India's pharmaceutical exports totaled Rs 2.3 lakh crore, an increase from Rs 1.1 lakh crore in FY14. Pharma exports increased by 8.36% from Rs 17,750 crore in July 2023 to Rs 18,670 crore in July 2024. The government anticipates that India's pharmaceutical market will achieve Rs 7.5 lakh crore by 2025, expanding at a rate of 10-12%, backed by robust domestic production and increasing exports. India holds the third position worldwide in drug production by volume and exports its products to more than 200 nations.Some companies experienced an increase in their market capitalisation, whereas others fell in the BT500 rankings even after implementing the right strategies. Sun Pharmaceutical Industries experienced a 45% increase in its market capitalisation, reaching Rs 3.5 lakh crore, climbing four positions in the BT500 ranking, as shareholders appear to positively endorse its strategies. The firm demonstrated consistent growth in FY24, with total sales increasing by 10% to Rs 47,759 crore. Sales of its formulation increased by 9.5% in the local market, reaching Rs 14,889 crore. Zydus Lifesciences announced an 80% rise in market capitalisation to Rs 92,068 crore, elevating its position by 13 spots in the BT500 ranking. Zydus's presentation showcases the achievement of broadening its product range and increasing its presence in important global markets. Companies like Sun Pharma, Zydus, Divi's Laboratories, and Cipla are well-placed to benefit from worldwide trends--diversifying pharmaceutical supply chains and increasing need for manufacturing solutions. POThe pharmaceutical sector in India ranks among the leading industries drawing investments. India's healthcare and pharmaceutical industries secured Rs 14,811 crore through initial public offerings (IPOs) in 2024, marking the highest amount since 2019, fueled by robust domestic demand and growing international prospects.Data indicates that significant contributors to the record fundraising were Sai Life Sciences (Rs 3,043 crore), IKS Health (Rs 2,498 crore), and Sagility India (Rs 2,107 crore). Although there were fewer IPOs this year (13 versus 21 last year), the average size of the issues experienced a significant increase.As per the draft red herring prospectus (DRHP) of Sai Life Sciences, "Resilient and sustainable long-term growth has been evident in the global pharmaceutical industry, particularly driven by an increase in chronic diseases, sedentary lifestyles, growth of the geriatric population, and increasing health consciousness."The global pharmaceutical market, estimated at $1,451 billion in 2023, is expected to expand at a compound annual growth rate (CAGR) of 6.2 percent and attain $1,956 billion by 2028. In India, the pharmaceutical industry ranks as one of the top ten most appealing sectors for foreign investment, with exports extending to more than 200 countries, including regulated markets such as the US and Europe."India accounts for 20 per cent of global generic drug exports by volume, positioning it as the largest global provider. Pharmaceutical exports totaled $ 25.3 billion in FY23, with March 2023 alone contributing $2.48 billion," according to the DRHP of Zenith Drugs. Experts feel that global drug shortages allow Indian drug makers to tap the export market. PO
< Page 8 | Page 10 >